Guest guest Posted April 5, 2006 Report Share Posted April 5, 2006 Lessons | Drugs | Forums | Blogs | News | Reading List | Cool ToolsPOZ.com | POZ Personals | POZ Mentor | Search | About Us | Home See "Recent Treatment News" stories at the end of this email. Newly updated lesson on Facial Wasting For many HIV-positive people, facial lipoatrophy (facial wasting) has become a frustrating reality. While facial lipoatrophy is not life-threatening, it is one of the most stigmatizing and troubling complications of HIV. Numerous studies and anecdotal reports have indicated that facial lipoatrophy can have detrimental effects on an affected person's self-confidence and quality of life, and can contribute significantly to depression. And because facial lipoatrophy is believed to be a side effect of anti-HIV therapy, it can significantly affect a person's "relationship" with his or her medications, possibly resulting in poor adherence or termination of therapy altogether, even if the medications are keeping viral load undetectable and the immune system healthy. While it is true that researchers still haven't determined the exact mechanism by which lipoatrophy occurs, progress is at hand. AIDSmeds.com's lesson on facial lipoatrophy focuses on what we do and don't know about it and includes a comprehensive overview of some of the treatments that are being studied (and approved) to help manage it. We've updated this lesson to include recent research on a complementary therapy called NucleomaxX, and and expanded section on semi-permanent and permanent fillers: Changes to Your Face (Facial Lipoatrophy) Truvada and HIV Prevention: The Hope Behind the Hype An injectable combo of tenofovir and emtricitabine (the oral pill combo formulation is called Truvada) was recently shown to protect six monkeys against repeated exposures to HIV. The future of this combo of drugs for pre-exposure prophylaxis (PREP) in people at high risk for HIV infection looks bright, but important questions remain. Read our news story on this important study: Truvada and HIV Prevention: The Hope Behind the Hype Development of NRTI Reverset Halted Incyte Corporation, one of the developers of dexelvucitabine (DFC), has announced that it is discontinuing development of the drug because of side effect concerns. DFC, formerly known as Reverset and apparently active against HIV resistant to current nucleoside reverse transcriptase inhibitors (NRTIs), caused significant elevated amylase levels in one clinical trial – a sign of possible pancreas damage. Regards, Vergelpowerusa dot org"I learned that...no one is perfect but most people are good; that people can't be judged only by the worst or weakest moments; that harsh judgements can make hypocrites of us all; that a lot of life is just showing up and hanging on; that laughter is often the best, and sometimes the only response to pain." My Life by Bill Clinton Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.